CMS certification 050047
California Pacific Medical Center- van Ness Campus
1101 van Ness Avenue, San Francisco, CA 94109
California Pacific Medical Center- van Ness Campus has a CMS overall rating of 3 out of 5 stars. 78% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 25 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on 2. Emergency patients spend a median of 3 h 18 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 478 completed surveys, 20% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | CA | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 356 visits sampled · US median for EDs of the same volume: 3 h 22 min | 3 h 18 min | 2 h 54 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 21 visits sampled | 5 h 19 min | 4 h 20 min | 4 h 17 min |
| Left before being seen Lower is better · 41,100 patients | 2% | 2% | 2% |
| Stroke symptoms: brain scan read within 45 minutes Higher is better · 22 patients | 91% | 74% | 69% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 119 patients | 71% | 70% | 65% |
How California Pacific Medical Center- van Ness Campus compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| California Pacific Medical Center- van Ness CampusThis hospital | 3/5 | 78% | 3 h 18 min | 1 better 2 worse |
| UCSF Health Saint Francis HospitalSame city | 3/5 | 61% | 2 h 18 min | 1 better 2 worse |
| California Pacific Medical Center - Mission BernalSame city | 4/5 | 76% | 3 h 24 min | 1 better 3 worse |
| Zuckerberg San Francisco General Hosp & Trauma CtrSame city | 2/5 | 72% | 5 h | 2 better 3 worse |
| Kaiser Foundation Hospital - San FranciscoSame city | 4/5 | 72% | — | 2 better |
| California Pacific Medical Ctr-Davies Campus HospSame city | 3/5 | 74% | 2 h 40 min | 1 better 1 worse |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in San Francisco.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 2,316 cases | Too few cases | 3.1% | 3.9% |
| Heart attack 143 cases | Too few cases | 10.5% | 11.9% |
| Heart failure 356 cases | Too few cases | 9.8% | 11.1% |
| Pneumonia 259 cases | Too few cases | 14.3% | 15.2% |
| Stroke 173 cases | Too few cases | 10.1% | 11.9% |
| COPD 60 cases | Too few cases | 10.3% | 8.6% |
| Heart bypass surgery (CABG) 55 cases | Too few cases | 2.6% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1.05 likely 0.81 – 1.28 | 1 |
| Deaths after a serious but treatable surgical complication 140 cases | No different | 192.86 per 1,000 likely 151.51 per 1,000 – 234.22 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 5,406 cases | No different | 0.33 per 1,000 likely 0 per 1,000 – 0.85 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 6,430 cases | No different | 0.31 per 1,000 likely 0.12 per 1,000 – 0.49 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 7,168 cases | No different | 0.28 per 1,000 likely 0.09 per 1,000 – 0.47 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 1,954 cases | No different | 2.63 per 1,000 likely 1.37 per 1,000 – 3.88 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 925 cases | No different | 2.47 per 1,000 likely 1.21 per 1,000 – 3.74 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 1,112 cases | No different | 10.13 per 1,000 likely 6.06 per 1,000 – 14.2 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 2,196 cases | No different | 3.3 per 1,000 likely 1.5 per 1,000 – 5.09 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 1,084 cases | No different | 7.26 per 1,000 likely 4.67 per 1,000 – 9.85 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 832 cases | No different | 1.67 per 1,000 likely 0.31 per 1,000 – 3.03 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 2,271 cases | No different | 1.14 per 1,000 likely 0.3 per 1,000 – 1.97 per 1,000 | 1.06 per 1,000 |
1 more measure had too few cases here to report.
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | Better | 0.33 likely 0.1 – 0.78 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0.22 likely 0.04 – 0.74 | 1 |
| Surgical site infections after colon surgery | No different | 1.72 likely 0.75 – 3.4 | 1 |
| MRSA bloodstream infections | No different | 0.44 likely 0.11 – 1.21 | 1 |
| C. diff intestinal infections | Better | 0.37 likely 0.25 – 0.54 | 1 |
1 more measure had too few cases here to report.
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 200 cases | Too few cases | 14.3% | 14.4% |
| Readmitted after heart failure 449 cases | Too few cases | 22.3% | 21.3% |
| Readmitted after pneumonia 293 cases | Too few cases | 19.2% | 17.3% |
| Readmitted after COPD 66 cases | Too few cases | 20.2% | 20% |
| Readmitted after heart bypass surgery 33 cases | Too few cases | 11% | 11% |
| Days back in hospital after a heart attack 187 cases | Too few cases | 18.2 days per 100 | — |
| Days back in hospital after heart failure 418 cases | Too few cases | 8.7 days per 100 | — |
| Days back in hospital after pneumonia 260 cases | Too few cases | 7.1 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 551 cases | No different | 12.5 per 1,000 likely 9.4 per 1,000 – 16.7 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 157 cases | No different | 10.2 per 100 likely 7.7 per 100 – 13.5 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 157 cases | No different | 5.2 per 100 likely 3.6 per 100 – 7.6 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 219 cases | No different | 0.9 likely 0.7 – 1.3 | — |
2 more measures had too few cases here to report.
Clinicians registered at this address
121 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 132 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Internal Medicine | 28 |
| Diagnostic Radiology | 14 |
| Anesthesiology | 11 |
| Pharmacist | 7 |
| Critical Care Medicine | 6 |
| Psychiatry | 6 |
| Acute Care | 5 |
| Emergency Medicine | 5 |
| Hospitalist | 5 |
| Physician Assistant | 4 |
| Registered Nurse | 4 |
| Vascular & Interventional Radiology | 4 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $1.6M
- 2020 $1.8M
- 2021 $2.6M
- 2022 $1.5M
- 2023 $913,619
- 2024 $1.7M
- 2025 $1.2M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Space rental and facility fees | $9,500 | 2 |
| Medical devices and supplies on long-term loan | $1,153 | 1 |
| Debt forgiveness | $29 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Merck Sharp & Dohme LLC | $919,333 | 7 |
| Abbvie INC. | $125,936 | 24 |
| PTC Therapeutics, Inc. | $38,370 | 3 |
| Regeneron Pharmaceuticals, Inc. | $34,288 | 6 |
| Argenx US, INC. | $25,955 | 20 |
| CSL Behring | $20,733 | 7 |
| Incyte Corporation | $8,000 | 1 |
| Medtronic, Inc. | $2,888 | 1 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| STUDY NAME#Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombination HR pathway g… Merck Sharp & Dohme LLC | $501,334 |
| Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombination HR pathway gene mutation Merck Sharp & Dohme LLC | $214,308 |
| A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not… Merck Sharp & Dohme LLC | $135,922 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OFPTC… PTC Therapeutics, Inc. · NCT05349721 | $38,370 |
| Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melano… Merck Sharp & Dohme LLC | $37,894 |
| Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR) Expressing, Platinum-sensitive Epithelial Ov… ABBVIE INC. · NCT05456685 | $31,280 |
| A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis ABBVIE INC. · NCT04948645 | $29,143 |
| A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Sub… ABBVIE INC. · NCT05578976 | $25,797 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about California Pacific Medical Center- van Ness Campus
Is California Pacific Medical Center- van Ness Campus a good hospital?
California Pacific Medical Center- van Ness Campus has a CMS overall rating of 3 out of 5 stars. Of the 25 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 1 and worse on 2. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend California Pacific Medical Center- van Ness Campus?
78% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 478 completed HCAHPS surveys.
How long is the wait in the California Pacific Medical Center- van Ness Campus emergency room?
Emergency patients spend a median of 3 h 18 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with high patient volume, like this one, the median is 3 h 22 min. 2% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does California Pacific Medical Center- van Ness Campus receive money from drug and device companies?
Drug and device makers reported $1.2M in payments to California Pacific Medical Center- van Ness Campus for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.